Clinical trials: Cutaneous Melanoma, Stage IV
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Malignant Melanoma
Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab
Determine the safety, tolerability, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of ACY-241 in combination with ipilimumab and nivolumab in patients with unresectable Stage…
- Trial name
- NCT02935790
- Testing
- ACY-241, nivolumab, ipilimumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Celgene
Melanoma (Skin)
SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma
RATIONALE: Surgery may be effective therapy in treating patients with metastatic melanoma. PURPOSE: This phase II trial is studying how well surgery works in treating patients with metastatic melanoma.
- Trial name
- NCT00002860
- Testing
- Surgery
- Where
- 124 sites in United States
- Volunteers
- 77 people
- Sponsor
- SWOG Cancer Research Network
Melanoma (Skin)
Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Interleukin-2 and sargramostim may stimulate a person's white blood cells to kill melanoma cells. PURPOSE: This phase II trial is studying how well giving interleukin-2 together with sargramostim works in treating…
- Trial name
- NCT00085579
- Testing
- aldesleukin, sargramostim, adjuvant therapy
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stage IV Melanoma
E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
Primary: Phase Ib: To define the safety, tolerability and maximum tolerated dose (MTD) of lenvatinib administered in combination with dacarbazine.
- Trial name
- NCT01133977
- Testing
- Lenvatinib, Dacarbazine
- Where
- 27 sites in United States, Germany and 3 more
- Volunteers
- 97 people
- Sponsor
- Eisai Inc.
Melanoma (Skin)
Study of Families With Melanoma
RATIONALE: A study that evaluates patients' lifestyle, skin, and blood and tissue samples may help doctors understand the risk factors for melanoma relapse.
- Trial name
- NCT00445783
- Testing
- gene expression analysis, mutation analysis, immunohistochemistry staining method
- Where
- United Kingdom
- Volunteers
- 3,700 people, healthy volunteers welcome
- Sponsor
- Leeds Cancer Centre at St. James's University Hospital
Cutaneous Metastatic Melanoma
Intratumoral Targeted Hyperthermia Therapy (THT) for Cutaneous Metastatic Melanoma
This device phase I/II, first in human, early feasibility study (EFS), open-label, single-arm trial aims to evaluate the safety, tolerability, and preliminary efficacy of Gold Nanorod (GNR)-enabled sub-ablative targeted…
- Trial name
- NCT06870994
- Testing
- Targeted Hyperthermia Therapy
- Volunteers
- 10 people
- Sponsor
- Sona Nanotech Inc
Recurrent Melanoma, Stage IV Melanoma
Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
This phase II trial studies intermittent dosing of BRAF inhibitor LGX818 (encorafenib) and MEK inhibitor MEK 162 (binimetinib) in treating patients with melanoma that has spread to other parts of the body (metastatic) and have a…
- Trial name
- NCT02263898
- Testing
- Raf kinase inhibitor LGX818, binimetinib, laboratory biomarker analysis
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Melanoma
A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy
This study will help determine whether 2 doses of the combination (ipilimumab + nivolumab) is sufficient for patients with early benefit compared to the usual way of trying to give 4 doses.
- Trial name
- NCT03122522
- Testing
- ipilimumab, nivolumab
- Where
- 13 sites in United States
- Volunteers
- 70 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
BRAF V600E Mutation Present, BRAF V600K Mutation Present
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
This randomized phase I trial studies the side effects and best way to give ipilimumab with or without dabrafenib, trametinib and/or nivolumab in treating patients with melanoma that has spread to other parts of the body…
- Conditions
- BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7
- Trial name
- NCT01940809
- Testing
- Dabrafenib, Ipilimumab, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma
The prognosis of patients with metastatic melanoma is poor and current available treatments are limited. Identification of a number of melanoma-specific tumor antigens that are shared by tumors from different patients, provides…
- Trial name
- NCT01944709
- Testing
- Dendritic cell application
- Where
- Switzerland
- Volunteers
- 2 people
- Sponsor
- Prof. Dr. Silke Gillessen
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma
RATIONALE: Vaccines made from a person's dendritic cells and antigens may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00074230
- Testing
- Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin
- Where
- Germany
- Volunteers
- 82 people
- Sponsor
- University Hospital Erlangen
Melanoma
Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients
The purpose of this study is to determine whether vaccination with tumor antigenic peptides and both CpG and Montanide adjuvants can induce an immune response in melanoma patients and to assess the safety of this vaccination.
- Trial name
- NCT00112229
- Testing
- group 1, group 2, group 3
- Where
- Switzerland
- Volunteers
- 29 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
This phase I trial studies the side effects and best dose of a modified virus called VSV-IFNbetaTYRP1 in treating patients with stage III-IV melanoma.
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Choroid Melanoma, Metastatic Melanoma
- Trial name
- NCT03865212
- Testing
- Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Castration-Resistant Prostate Carcinoma, Metastatic Colorectal Carcinoma
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
This trial compares cryoablation combined with stereotactic body radiation therapy to stereotactic body radiation therapy alone to see how well they work in treating patients with pain from cancer that has spread to the bones…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04693377
- Testing
- Cryosurgery, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma, Melanoma Stage IV
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors.
- Conditions
- Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
- Trial name
- NCT04478279
- Testing
- ST101, Temozolomide, Radiation
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 125 people
- Sponsor
- Sapience Therapeutics
Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
This phase II trial studies how well glembatumumab vedotin works in treating patients with middle layer of the wall of the eye (uveal) melanoma that has spread to other parts of the body (metastatic) or has returned at or near…
- Trial name
- NCT02363283
- Testing
- Glembatumumab Vedotin, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 25 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Melanoma, Stage III and IV Melanoma
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.
A dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanomas.
- Trial name
- NCT00688090
- Testing
- Biological: MKC1106-MT, Biological: MKCC1106-MT
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Mannkind Corporation
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
This phase I trial studies the side effects and best dose of ziv-aflibercept when given together with pembrolizumab in treating patients with solid tumors that that may have spread from where it first started to nearby tissue…
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma
- Trial name
- NCT02298959
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 9 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Melanoma, Stage IIIB Skin Melanoma
Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
This phase II trial is studying how well giving temsirolimus together with bevacizumab works in treating patients with stage III or stage IV malignant melanoma.
- Conditions
- Recurrent Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
- Trial name
- Mel47 (NCT00397982)
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)